Effectiveness of Virtual Reality Vision Therapy - VERVE

Description

The purpose of this research study is to see how well the treatment of a participant's eye coordination and/or focusing problems improves eye muscle responses and symptoms of eyestrain. We will use an entertainment device called a virtual reality headset to play a custom-designed video game to find out how well the treatment of binocular vision improves a participant's coordination and/or focusing problem. The virtual reality headset uses eye-trackers to monitor progress in a totally objective manner. Objective testing allows the doctor to determine the results without relying on a participant's ability to answer questions or respond verbally in any way. We will compare the results of a participant before and after playing the video game.

Conditions

Convergence Insufficiency

Study Overview

Study Details

Study overview

The purpose of this research study is to see how well the treatment of a participant's eye coordination and/or focusing problems improves eye muscle responses and symptoms of eyestrain. We will use an entertainment device called a virtual reality headset to play a custom-designed video game to find out how well the treatment of binocular vision improves a participant's coordination and/or focusing problem. The virtual reality headset uses eye-trackers to monitor progress in a totally objective manner. Objective testing allows the doctor to determine the results without relying on a participant's ability to answer questions or respond verbally in any way. We will compare the results of a participant before and after playing the video game.

Effectiveness of Vision Therapy in a Virtual Reality Headset

Effectiveness of Virtual Reality Vision Therapy - VERVE

Condition
Convergence Insufficiency
Intervention / Treatment

-

Contacts and Locations

Newark

OculoMotor Technologies, Newark, New Jersey, United States, 07103

Philadelphia

The Eye Institute at Salus University, Philadelphia, Pennsylvania, United States, 19141

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 9 years and older
  • * CISS score ≥ 16
  • * Best-corrected distance visual acuity of 20/25 or better in each eye
  • * Random dot stereopsis appreciation of 500 seconds of arc or better
  • * Parent or subject understands the protocol and is willing to enroll in the study
  • * Constant strabismus at distance or near
  • * Vertical heterophoria ≥ 2 ∆ at distance or near
  • * ≥ 2 line interocular difference in best-corrected visual acuity
  • * Near point of accommodation \> 20 cm in either eye as measured by push-up method
  • * Manifest or latent nystagmus
  • * Non-strabismic binocular vision and accommodative disorders associated with known disease of the brain
  • * Diseases known to affect accommodation, vergence, or ocular motility such as multiple sclerosis, Graves orbitopathy, myasthenia gravis, diabetes mellitus, Parkinson disease
  • * Any ocular or systemic medication known to affect accommodation or vergence such as anti-anxiety agents (e.g., Librium or Valium), anti-arrhythmic agents (e.g., Cifenline, Cibenzoline), anti-cholinergics, bladder spasmolytic drugs (e.g., Propiverine), hydroxychloroquine, chloroquine, phenothiazines (e.g., Compazine, Mellaril, Thorazine), tricyclic antidepressants (e.g., Elavil, Nortriptyline, Tofranil)
  • * Inability to comprehend and/or perform any study-related test or procedure

Ages Eligible for Study

9 Years to 35 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

OculoMotor Technologies,

Chang Yaramothu, PhD, STUDY_CHAIR, OculoMotor Technologies

Tara L Alvarez, PhD, PRINCIPAL_INVESTIGATOR, OculoMotor Technologies

Mitchell M Scheiman, OD, PhD, PRINCIPAL_INVESTIGATOR, OculoMotor Technologies

Study Record Dates

2024-09